Ipamorelin vs CJC-1295: Head-to-Head Efficacy Compared
HealthRX.com
No head-to-head trial compares these two peptides
From the public record
Published papers: ipamorelin and CJC-1295
PubMed indexes 51 papers that mention ipamorelin in the title or abstract and 35 that mention CJC-1295. In 2025 the counts were 0 and 1.
| Measure | Value |
|---|---|
| ipamorelin: papers, all years | 51 |
| CJC-1295: papers, all years | 35 |
| ipamorelin: papers, 2016 to 2025 | 15 |
| CJC-1295: papers, 2016 to 2025 | 15 |
| ipamorelin: papers in 2025 | 0 |
| CJC-1295: papers in 2025 | 1 |
How this was calculated
Ran a PubMed title and abstract search for each name separately and recorded counts by publication year. No filtering by study type or quality.
PubMed records with each name in the title or abstract, all article types and species; a paper naming both counts for each
Paper counts show research attention, not which option works better. A paper that mentions a compound is not evidence that it works or is safe in people. Counts include animal, cell, review and opinion papers.
At a glance
- Ipamorelin human record / One published phase 2 trial in bowel surgery (negative) and one intravenous PK/PD study in healthy men [2][5]
- CJC-1295 human record / Three published studies, all the DAC form, all in healthy volunteers [3]
- CJC-1295 hormone effect / Mean GH up 2- to 10-fold for six days or more and IGF-I up 1.5- to 3-fold after one injection [1]
- Half-life / Ipamorelin about 2 hours after IV dosing [5]; CJC-1295 DAC 5.8 to 8.1 days [1]
- FDA approval / Neither peptide [3][4]
- WADA status / Both prohibited at all times [6]
How Do the Human Studies Differ?
The two human programmes are not even the same kind of evidence. CJC-1295's human studies measured growth hormone and IGF-I in healthy volunteers after subcutaneous injections [1][7]. Ipamorelin's human studies used intravenous dosing: one in patients recovering from bowel surgery, one in healthy men [2][5]. FDA found no human pharmacokinetic, safety or efficacy data for subcutaneous ipamorelin at all [4].
What Each Peptide Does at Its Receptor
Ipamorelin is a five-amino-acid synthetic peptide that stimulates GH release at the ghrelin/GH-secretagogue receptor rather than at the GHRH receptor [4][8]. In rats and pigs it released GH with potency similar to GHRP-6, and in swine it did not change FSH, LH, prolactin or TSH levels [8]. Nearly everything said about ipamorelin's selectivity comes from that animal work.
CJC-1295 is a 29-amino-acid GHRH analogue that acts on the pituitary the way GHRH does, raising the body's own GH and, through GH, IGF-I [3][1]. The DAC form carries an extra maleimidopropionic acid-lysine unit that lets it bind blood albumin, so its half-life is measured in days rather than minutes [3][1].
Ipamorelin and CJC-1295 act at different receptors, but the human studies tested each peptide alone [1][2].
Ipamorelin: What the Human Trials Measured
The published efficacy trial (Beck 2014) enrolled 117 adults undergoing small or large bowel resection, of whom 114 were analysed. They received 0.03 mg/kg ipamorelin or placebo intravenously twice daily from postoperative day 1 to day 7 or discharge. Median time to first tolerated solid meal was 25.3 hours on ipamorelin and 32.6 hours on placebo, a difference that was not statistically significant (p=0.15). Secondary measures of gut recovery did not differ; only a subgroup of open-surgery patients showed faster bowel recovery [2]. Development for this use was reportedly discontinued after disappointing phase 2 results [4].
The other human study (Gobburu 1999) gave healthy men 15-minute intravenous infusions ranging from 4.21 to 140.45 nmol/kg. Terminal half-life was about 2 hours, GH rose in a single sharp peak about 0.67 hours after the infusion, and GH fell to negligible levels at every dose [5]. That study had no efficacy endpoint.
The only efficacy endpoint in the published ipamorelin human work was recovery after bowel surgery, and it missed its main endpoint [2].
CJC-1295: What the Human Trials Measured
FDA identified three published human studies of CJC-1295, all using the DAC form in healthy volunteers. FDA found no study of any form of CJC-1295 in people with a disease. A trial in HIV-associated visceral obesity listed on ClinicalTrials.gov was terminated [3].
Teichman 2006 ran two randomised, placebo-controlled, double-blind, ascending-dose trials lasting 28 and 49 days in healthy adults aged 21 to 61. Study 1 used single subcutaneous doses; study 2 used two or three weekly or biweekly doses [1]. After a single injection, mean plasma GH rose 2- to 10-fold for six days or more and mean IGF-I rose 1.5- to 3-fold for 9 to 11 days. Estimated half-life was 5.8 to 8.1 days, and after multiple doses IGF-I stayed above baseline for up to 28 days. No serious adverse reactions were reported [1]. FDA counted 35 treated subjects and 7 on placebo in study 1 [3].
Ionescu and Frohman 2006 gave healthy men aged 20 to 40 a single injection of 60 or 90 micrograms/kg. A week later GH pulsatility was preserved — pulse frequency and size unchanged — but trough GH had risen about 7.5-fold, mean GH 46% and IGF-I 45%. There was no difference between the two doses [7].
Those numbers describe hormone levels, not health outcomes, and they come from the DAC form: FDA found no human study of the version sold as CJC-1295 without DAC [3].
So Which One Is More Effective?
No trial compared the two peptides directly. Ipamorelin's bowel-surgery trial measured time to tolerate a solid meal but did not find a statistically significant benefit; the published CJC-1295 studies measured hormone levels in healthy volunteers [2][3]. CJC-1295 DAC kept IGF-I above baseline for 9 to 11 days after one subcutaneous injection [1]. Intravenous ipamorelin produced a single GH peak about 0.67 hours after infusion [5]. These results do not establish which peptide has a longer overall hormone effect.
A peptide that raises IGF-I by 45% has shown that it raises IGF-I, not that it changes muscle, fat, recovery or sleep [7]. A head-to-head comparison would also be tangled by route, since every human dose of ipamorelin in these studies was intravenous while the CJC-1295 human doses were subcutaneous [1][2][5].
Questions worth asking
Side Effects in the Human Studies
In the ipamorelin ileus trial, low potassium occurred in 12.5% of ipamorelin patients versus 3.4% on placebo; insomnia in 10.7% versus 5.2%; high blood sugar at discharge in 14.3% versus 8.6%; serious adverse events in 17.9% versus 15.5%. Two ipamorelin-treated patients died of surgical complications after bowel surgery for colon cancer with anastomotic leak; FDA said it is unclear whether the deaths were related to ipamorelin but that they raise safety concerns [4][2].
For CJC-1295, per FDA's summary of the Teichman trials: injection-site reactions in about 70% of subjects in study 1 and in all treated subjects in study 2; headache in 63% versus 14% on placebo in study 1; flushing, warmth and transient low blood pressure in about 30% of treated subjects in study 1; and transient diarrhoea. Most events were more common at the higher doses, and no serious adverse reactions were reported [3][1]. In the Ionescu study, heart rate rose with dose and injection sites were transiently red and tender [3].
One event sits outside the published trials. FDA's briefing says ConjuChem withdrew CJC-1295 DAC from clinical trials in 2006 after a participant in a phase 2 trial in HIV lipodystrophy (192 enrolled) died. According to news reports cited by FDA, the person had chest discomfort 2 hours after an 11th weekly dose, and the attending physician's most likely explanation was undiagnosed coronary artery disease with plaque rupture. The data were never published, so a causal link is neither shown nor excluded [3].
The broader concern applies to both. Raising GH and IGF-I carries the risks listed on approved growth hormone labels — glucose intolerance and diabetes, fluid retention, tumour growth concerns — and the human studies were short, small and mostly single-dose, so long-term safety is unknown [3][4].
Regulatory Status of Both Peptides
Neither is approved. FDA searched 12 countries and the European Medicines Agency's authorisations in December 2024 and found no approved product containing any form of CJC-1295 [3]. Ipamorelin has never been approved, is not a component of any approved drug and has no USP monograph [4].
For compounding, FDA lists ipamorelin acetate in category 2 — bulk substances that may present significant safety risks — for outsourcing facilities, where it has sat since 29 September 2023 and is still listed on the page dated 22 April 2026 [9][10]. FDA's stated concerns include possible immunogenicity, unnatural amino acids that complicate characterisation, and serious adverse events including death when ipamorelin was given intravenously for gastric motility [9]. CJC-1295 now sits in the nominated-but-withdrawn table, but FDA still posts its concerns: possible immunogenicity for certain routes, impurity and characterisation problems, serious adverse events including increased heart rate and systemic vasodilatory reaction, and limited clinical data [9].
FDA's Pharmacy Compounding Advisory Committee voted against adding both. In October 2024 the ipamorelin vote was 0 yes, 12 no and 1 abstention for both the free base and the acetate [11]. In December 2024 the CJC-1295 votes were 0 yes and 13 no for the free base, 1 yes and 12 no for the acetate, and 0 yes and 13 no for each of the three DAC forms [12]. Neither appears in HHS's October 2026 draft enforcement-discretion policy, which names six other peptides [13].
In sport, WADA lists both in section S2.2.4 as growth hormone secretagogues and GHRH analogues, prohibited at all times in and out of competition on both the 2026 and 2027 Prohibited Lists [6][14].
Check what you know
Question 1 of 3
Score: 0 right, 0 of 3 answered
Frequently asked questions
Is ipamorelin better than CJC-1295?
Has ipamorelin been tested with subcutaneous injections in humans?
Is CJC-1295 without DAC the same as CJC-1295 with DAC?
Does stacking ipamorelin with CJC-1295 work better than either alone?
Do either of these peptides build muscle?
References
Show all 14 referencesHide references
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805.
- Beck DE, Sweeney WB, McCarter MD, Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29(12):1527-34.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-6.
- World Anti-Doping Agency.
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-7.
- Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Official web page.
- World Anti-Doping Agency.